LEXXEL Drug Patent Profile

« Back to Dashboard

Which patents cover Lexxel, and what generic alternatives are available?

Lexxel is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in LEXXEL is enalapril maleate; felodipine. Additional details are available on the enalapril maleate; felodipine profile page.

Summary for LEXXEL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LEXXEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-002	Oct 28, 1998		DISCN	No	No
Astrazeneca	LEXXEL	enalapril maleate; felodipine	TABLET, EXTENDED RELEASE;ORAL	020668-001	Dec 27, 1996		DISCN	No	No

International Patents for LEXXEL

See the table below for patents covering LEXXEL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	1237
Australia	4831679
Australia	529116
Bulgaria	61420
Canada	1117530	3,5-DIESTERS ASSYMETRIQUES DE 2,6-DIMETHYL-4-2,3- PHENYL DISUBSTITUE-1,4-DIHYDROPYRIDINE-3,5-ACIDE DICARBOXYLIQUE, AYANT DES PROPRIETES D'HYPOTENSEURS; METHODE DE PREPARATION, ET PREPARATION PHARMACEUTIQUE A BASE DE CES PRODUITS (2,6-DIMETHYL-4-2,3-DISUBSTITUTED PHENYL-1,4- DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID-3,5-ASYMMETRIC DIESTERS HAVING HYPOTENSIVE PROPERTIES AS WELL AS PROCESS FOR THEIR PREPARATIONAND PHARMACEUTICAL PREPARATION CONTAINING SAME)
Czechoslovakia	241021	METHOD OF 2,6-DIMETHYL-4-(I8O-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYL ACID'S 3-METHYL-5-ETHYLESTER PRODUCTION
Czechoslovakia	241038	METHOD OF 2,6-DIMETHYL-4-(2,3-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYL ACID'S 3-METHYL-5-ETHYL-ESTER PRODUCTION

Supplementary Protection Certificates for LEXXEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0007293	SPC/GB93/134	United Kingdom
0007293	95C0001	Belgium		PRODUCT NAME: FELODIPINE, METOPOLOL SUCCINATE; NAT. REGISTRATION NO/DATE: 122 IS 160 F 3 / 19921230; FIRST REGISTRATION: DK 8678 19921230

Investment Scenario and Fundamentals Analysis for Levetiracetam (LEXXEL)

Last updated: February 24, 2026

What is Levetiracetam (LEXXEL)?

Levetiracetam, marketed under the brand name LEXXEL, is an antiepileptic drug primarily used for the treatment of partial-onset seizures and generalized seizures. It is a second-generation drug with a broad therapeutic window and favorable side-effect profile compared to first-generation AEDs.

Market Overview

Global Epilepsy Drug Market

• Valued at approximately USD 4.2 billion in 2022.
• Projected CAGR of 4.8% from 2023 to 2030 ([1]).
• Market growth driven by increased epilepsy prevalence, expanding indications, and the adoption of newer AEDs like LEXXEL.

LEXXEL Position and Market Share

• LEXXEL is a generic version of levetiracetam.
• Dominates markets in the US, European Union, and emerging markets.
• Estimated global sales for LEXXEL equivalent products reached USD 800 million in 2022.

Investment Fundamentals

Clinical Efficacy and Safety

LEXXEL exhibits comparable efficacy to branded levetiracetam (Keppra) with a favorable safety profile. The drug's pharmacokinetic properties include:

• Rapid absorption with peak plasma concentrations within 1 hour.
• Bioavailability exceeds 95%.
• Renal excretion without significant hepatic metabolism.

The safety profile supports long-term use and patient adherence.

Regulatory Status and Approvals

• Approved by the FDA in 2008.
• EMA approval followed in 2006.
• Regulatory pathways for generics typically involve abbreviated New Drug Application (ANDA).

Manufacturing and Supply Chain

• Proven manufacturing processes with scalable synthesis.
• Dependence on active pharmaceutical ingredient (API) suppliers in India and China.
• Recent supply chain disruptions increased scrutiny but remain manageable due to multiple sourcing options.

Competitive Landscape

Competitor	Market Share (2022)	Pricing Strategy	Key Differentiators
Original Brand (Keppra)	60%	Premium pricing	Brand recognition, physician preference
LEXXEL (Generic)	25%	20-30% lower	Cost advantage, expanding formulary acceptance
Other Generics	15%	Similar pricing	Price competition, limited brand recognition

Investment Risks

• Patent expiry of branded Keppra (2015) resulted in market flooding with generics.
• Market saturation and pricing pressure reduce profit margins.
• Regulatory hurdles for entry into emerging markets.
• Potential for drug modifications or new therapies to displace levetiracetam.

Financial Outlook

Revenue Projections

• US generic levetiracetam sales projected to grow at 2-3% annually over the next five years.
• Margins: Historically, generic AEDs offer gross margins of 20-30%, influenced by API costs and competitive pricing.
• Key growth in emerging markets driven by cost-conscious healthcare systems.

Investment Vehicles

• Stock investments in generic drug manufacturers such as Teva, Mylan (now part of ViacomCBS), and Dr. Reddy's.
• Private equity investments in specialty generics and API suppliers.

Policy and Market Trends

• Increasing adoption of generic drugs due to cost containment policies.
• Regulatory incentives for manufacturing in developing countries.
• Price regulation pressures in key markets like the US and EU.

Key Takeaways

• LEXXEL is a cost-effective alternative to branded levetiracetam with stable market demand.
• The market is mature but continues to grow at a moderate pace.
• Margins are under pressure from pricing competition, especially after patent expirations.
• Supply chain resilience remains critical in current geopolitical climates.
• Investment returns depend on market penetration, API sourcing, and regulatory dynamics.

FAQs

What are the primary factors influencing LEXXEL’s market growth?
Competitive pricing, increasing epilepsy prevalence, and expanding acceptance of generics underpin growth.

How does patent expiration impact generic levetiracetam sales?
Patent expiry in 2015 triggered market entry of multiple generics, increasing competition but lowering prices.

What are the regulatory challenges for generic levetiracetam?
Ensuring bioequivalence, managing supply chain compliance, and gaining market approval in emerging regions.

Can market saturation diminish LEXXEL’s profitability?
Yes, matured markets with high generic penetration face pricing pressure that can erode margins.

What are key strategic considerations for investors?
Focus on companies with diversified generic portfolios, robust API sourcing, and emerging market expansion plans.

References

[1] Allied Market Research. (2023). Epilepsy Drugs Market by Type, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast.